ARIPIPRAZOLE

acesulfame potassium,aspartame,calcium silicate,croscarmellose sodium,crospovidone,crème de vanilla (natural and artificial flavors),magnesium stearate,microcrystalline cellulose,silicon dioxide,tartaric acid,xylitol,ferric oxide (yellow or red),FD&C Blue No. 2 Aluminum Lake,phenylalanine

ABILIFY is indicated for the treatment of schizophrenia. The efficacy of ABILIFY in the treatment of schizophrenia was established in short-term (4- and 6-week) controlled trials of schizophrenic inpatients (see CLINICAL PHARMACOLOGY: Clinical Studies).

The efficacy of ABILIFY in maintaining stability in patients with schizophrenia who had been symptomatically stable on other antipsychotic medications for periods of 3 months or longer, were discontinued from those other medications, and were then administered ABILIFY 15 mg/day and observed for relapse during a period of up to 26 weeks was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Studies). The physician who elects to use ABILIFY for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).